# KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

> **NCT04237649** · EARLY_PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 77 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** KAZ954
- **DRUG:** PDR001
- **DRUG:** NIR178
- **DRUG:** NZV930

## Key facts

- **NCT ID:** NCT04237649
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-02-20
- **Primary completion:** 2023-09-15
- **Final completion:** 2023-09-15
- **Target enrollment:** 77 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04237649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04237649, "KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04237649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*